Sees FY24 revenue $385M-$400M, consensus $363.95M.”We are encouraged by our strong fourth-quarter results, driven by improved execution across both software and services,” said William F. Feehery, Chief Executive Officer. “Certara is well positioned to grow in 2024, supporting continued investment in new software products, including expanded artificial intelligence capabilities, as well as commercial activity. The long-term prospects for biosimulation remain very compelling and we are investing to support the growth we see ahead for the company.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on CERT:
- Certara Reports Fourth Quarter 2023 Financial Results
- Certara initiated with a Market Perform at Leerink
- Certara to Report Fourth Quarter and Full Year 2023 Financial Results on February 29th, 2024 and Participate in the Barclays 26th Annual Global Healthcare Conference
- Certara price target raised to $18 from $16 at Barclays
